需要急性血液透析的严重高钙血症:一项回顾性队列研究显示新冠疫情期间发病率增加
该研究在摩洛哥乌季达穆罕默德六世大学医院肾内科回顾了84个月(2014年9月至2021年9月)的成人严重高钙血症(校正总血钙>3.5 mmol/l或>14.0 mg/dl)并接受一次或多次血液透析的患者。共纳入64例患者的66次发作,平均年龄57±15岁,女性57.6%,入院平均校正血钙16.9±2.1 mg/dl,33.3%超过18.0 mg/dl,恶性肿瘤占病因的80.4%,急性肾损伤占69.7%,死亡率14%。新冠疫情期间与前相比,新诊断肿瘤15.4% vs 23.7%(p=0.31),严重高钙血症(>16.0 mg/dl)25% vs 50%(p=0.03),死亡率35.7% vs 52.6%(p=0.13)。作者结论认为新冠疫情期间高钙血症的发病率和严重程度均增加,在此背景下血液透析仍有效且安全。
要点
- 严重高钙血症定义为校正总血钙>3.5 mmol/l或>14.0 mg/dl,且需接受一次或多次血液透析。
- 恶性肿瘤占病因的80.4%,急性肾损伤发生率为69.7%。
- 入院平均校正血钙16.9±2.1 mg/dl,33.3%的患者超过18.0 mg/dl。
- 心电图异常在三组间分别为58.3%、87.5%和85.7%(p=0.04);平均血钾分别为5.1±1.3、4.0±1.0和3.7±0.7(p<0.001)。
- 新冠疫情期间严重高钙血症(>16.0 mg/dl)比例较疫情前升高(25% vs 50%,p=0.03)。
适用人群与场景
- 成人患者,诊断为严重高钙血症并接受一次或多次血液透析。
- 研究地点为摩洛哥乌季达穆罕默德六世大学医院肾内科,研究期为2014年9月至2021年9月共84个月。
诊断标准与关键阈值
- 严重高钙血症定义为校正总血清钙>3.5 mmol/l或>14.0 mg/dl。
- 纳入标准:所有诊断为严重高钙血症并接受一次或多次血液透析的成人患者。
处置流程与药物剂量
- 开始医学治疗后48小时血清钙下降幅度为4.64±1.63 mg/dl。
- 血液透析在此背景下仍有效且安全(原文结论)。
红旗征与不能漏的情况
- 心电图异常在高钙血症患者中常见,三组(14.0-16.0 mg/dl、16.1-18.0 mg/dl、>18.0 mg/dl)发生率分别为58.3%、87.5%和85.7%(p=0.04)。
- 平均血钾在组1(14.0-16.0 mg/dl)为5.1±1.3,组2(16.1-18.0 mg/dl)为4.0±1.0,组3(>18.0 mg/dl)为3.7±0.7(p<0.001)。
研究设计与关键结果
- 研究为回顾性研究,共纳入64例患者的66次严重高钙血症发作;平均年龄57±15岁,女性占57.6%。
- 入院平均校正血清钙为16.9±2.1 mg/dl,33.3%的患者超过18.0 mg/dl。
- 恶性肿瘤占所有病因的80.4%;急性肾损伤发生率为69.7%。
- 总死亡率为14%。
- 心电图异常发生率在三组间分别为58.3%、87.5%和85.7%(p=0.04);平均血钾分别为5.1±1.3、4.0±1.0和3.7±0.7(p<0.001)。
- 新冠疫情期间 vs 疫情前:新诊断肿瘤15.4% vs 23.7%(p=0.31);严重高钙血症(>16.0 mg/dl)25% vs 50%(p=0.03);死亡率35.7% vs 52.6%(p=0.13)。
- 作者结论认为新冠疫情期间高钙血症的发病率和严重程度均增加,此背景下血液透析仍有效且安全。
证据类型、等级与局限
- 证据类型:回顾性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 新冠疫情期间严重高钙血症(>16.0 mg/dl)比例较疫情前升高(25% vs 50%,p=0.03),提示临床需关注该时段高钙血症的严重程度变化。
- 血液透析在此背景下仍有效且安全(原文结论),可用于需要急性透析的严重高钙血症患者。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The Covid-19 pandemic has had dramatic consequences on the progression of numerous pathologies, especially neoplastic ones. The orientation of hospital activities toward the care of patients with SARS-Cov2 infection has caused significant delays in the diagnosis and therapy of many other pathologies. What about severe hypercalcemia? The aim of this work was to determine the clinical and biological presentation, etiologies, mortality, and the impact of the Covid-19 pandemic on severe hypercalcemia.
MATERIAL AND METHODS: we conducted a retrospective study for 84 months (September 2014 to September 2021) at the Nephrology Unit in University Hospital Mohammed VI, Oujda, Morocco. Included were all adult patients diagnosed with severe hypercalcemia (defined as corrected total serum calcium of >3.5 mmol/l or > 14.0 mg/dl) and who had benefited from one or more hemodialysis sessions.
RESULTS: 66 episodes of severe hypercalcemia occurred in 64 patients. The mean age was 57 ± 15 years and 57.6% were female. The mean corrected serum calcium at admission was 16.9 ± 2.1 mg/dl and 33.3% had more than 18.0 mg/dl. Malignancies represented 80.4% of all etiologies. Acute kidney injury was observed in 69.7%. The delta drop in serum calcium 48 h after initiation of medical treatment was 4.64 ± 1.63 mg /dl. Mortality was noted in 14% of all cases. Electrocardiographic abnormalities were observed in 58.3%, 87.5% and 85.7%, respectively, in group 1 (14.0-16.0 mg/dl), group 2 (16.1-18.0 mg/dl), and group 3 (> 18.0 mg/dl) (p = 0.04). The mean serum potassium value was 5.1 ± 1.3, 4.0 ± 1.0, and 3.7 ± 0.7 respectively, in group 1 (14.0-16.0 mg/dl), group 2 (16.1-18.0 mg/dl), and group 3 (> 18.0 mg/dl) (p < 0.001). Newly diagnosed neoplasia, severe hypercalcemia (> 16.0 mg/dl), and mortality have been observed in 15.4% vs. 23.7% (p = 0.31), 25% vs. 50% (p = 0.03), and 35.7% vs. 52.6% (p = 0.13) respectively, in patients before and during the Covid-19 pandemic.
CONCLUSIONS: The Covid-19 pandemic caused an increase in both the incidence and severity of hypercalcemia and the hemodialysis practiced in this context remains efficient and safe.
参考来源
- Bentata Y, Benabdelhak M, Haddiya I, et al. Severe hypercalcemia requiring acute hemodialysis: A retrospective cohort study with increased incidence during the Covid-19 pandemic. Am J Emerg Med. 2021. PMID: 34823193. doi:10.1016/j.ajem.2021.11.013
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。